QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Forecast, Price & News

$1.69
-0.02 (-1.17%)
(As of 05/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.64
$1.78
50-Day Range
$1.67
$3.27
52-Week Range
$1.61
$6.15
Volume
546,476 shs
Average Volume
566,904 shs
Market Capitalization
$125.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.19
30 days | 90 days | 365 days | Advanced Chart
Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Pieris Pharmaceuticals logo

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Headlines

Pieris Pharmaceuticals Q1 2022 Earnings Preview
This Pharmaceutical Stock Could Bank Billions Soon
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PIRS
Employees
124
Year Founded
N/A

Sales & Book Value

Annual Sales
$31.42 million
Book Value
$0.70 per share

Profitability

Net Income
$-45.74 million
Net Margins
-175.99%
Pretax Margin
-145.58%

Debt

Price-To-Earnings

Miscellaneous

Free Float
69,825,000
Market Cap
$125.23 million
Optionable
Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/16/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.94 out of 5 stars

Medical Sector

658th out of 1,423 stocks

Pharmaceutical Preparations Industry

306th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

Is Pieris Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pieris Pharmaceuticals stock.
View analyst ratings for Pieris Pharmaceuticals
or view top-rated stocks.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Pieris Pharmaceuticals
.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.05. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 93.41% and a negative net margin of 175.99%. During the same period in the previous year, the company posted ($0.07) earnings per share.
View Pieris Pharmaceuticals' earnings history
.

What price target have analysts set for PIRS?

2 analysts have issued twelve-month price objectives for Pieris Pharmaceuticals' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 373.4% from the stock's current price.
View analysts' price targets for Pieris Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Pieris Pharmaceuticals' key executives?
Pieris Pharmaceuticals' management team includes the following people:
  • Mr. Stephen S. Yoder, CEO, Pres & Director (Age 46, Pay $730.13k)
  • Mr. Thomas Bures, Sr. VP & CFO (Age 48, Pay $360.51k)
  • Dr. Hitto Kaufmann Ph.D., Sr. VP & Chief Scientific Officer (Age 51, Pay $458.68k)
  • Maria Kelman, Exec. Director of Investor Relations
  • Mr. Ahmed S. Mousa J.D., Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec. (Age 38)
  • Mr. Frank Vollmering, VP of HR
  • Dr. Christine Rothe Ph.D., VP and Head of Early Stage Project Leadership & Data Science
  • Dr. Shane Olwill Ph.D., Sr. VP & Chief Devel. Officer
  • Mr. Prompong Chaikul, Chief Supply Chain Officer (Age 35)
  • Dr. Tim Demuth M.D., Ph.D., Sr. VP & Chief Medical Officer
What other stocks do shareholders of Pieris Pharmaceuticals own?
What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Woodline Partners LP (2.14%), BlackRock Inc. (1.81%), Assenagon Asset Management S.A. (1.63%), Citigroup Inc. (0.65%), Healthcare of Ontario Pension Plan Trust Fund (0.56%) and Cutter & CO Brokerage Inc. (0.55%). Company insiders that own Pieris Pharmaceuticals stock include Aquilo Capital Management, Llc, Shane Olwill and Tim Demuth.
View institutional ownership trends for Pieris Pharmaceuticals
.

Which major investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Goldman Sachs Group Inc., Assenagon Asset Management S.A., Connor Clark & Lunn Investment Management Ltd., Citigroup Inc., Group One Trading L.P., and Simplex Trading LLC.
View insider buying and selling activity for Pieris Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Pieris Pharmaceuticals stock?

PIRS stock was bought by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, JPMorgan Chase & Co., Renaissance Technologies LLC, State Street Corp, UBS Group AG, BlackRock Inc., Commerce Bank, and Bailard Inc..
View insider buying and selling activity for Pieris Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $1.69.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals has a market capitalization of $125.23 million and generates $31.42 million in revenue each year. The biotechnology company earns $-45.74 million in net income (profit) each year or ($0.69) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

Pieris Pharmaceuticals employs 124 workers across the globe.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is www.pieris.com.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at (857) 246-8998, via email at [email protected], or via fax at 49-8161-141-1444.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.